Topic: cardiovascular disease
The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.
It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.
Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.
Phase 3 data for PCSK9-targeting RNAi drug inclisiran show it has the efficacy and clean safety profile to hang with Repatha and Praluent.
Boehringer and Lilly's new video series teams a cardiologist host, a dog and a guest physician to raise awareness of diabetes-related heart disease.
Fitness coach and heart attack survivor Bob Harper hits the road to meet with fellow heart patients in next phase of AstraZeneca’s awareness campaign.
Aiming to protect Vascepa's CV advantage—and its fast-growing prescription count—Amarin's fighting supplement makers in court.
AstraZeneca's latest diabetes awareness rollout features a fisherman who likens his stalling boat engine to a bad heart.
Call it a promise kept. Amarin has staunchly promised that Vascepa could prove it cuts heart risks, despite detractors' disbelief—and now it has.
The 2018 European Society of Cardiology Congress presented some bombshell data that would shake up the cardiovascular landscape in the coming year.